NOEMA · NOE-TSC-201
Public neurological clinical research study information. Check the current recruitment status in the live Wix study record.
A Phase 2B, Multicenter, 30-week, Prospective, Cross-over, Double-blind, Randomized, Placebo-controlled Study Followed by a 52-Week Open-label Extension Study to Evaluate the Efficacy and Safety of Basimglurant Adjunctive to Ongoing Anticonvulsive Therapy in Children, Adolescents, and Young Adults with Seizures Associated with Tuberous Sclerosis Complex. EudraCT: 2021-000838-34
Sponsor: NOEMA PHARMA
Phase: II
Area: Epilepsy